Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Rating) shares gapped up prior to trading on Wednesday . The stock had previously closed at $12.76, but opened at $13.60. Cullinan Oncology shares last traded at $12.84, with a volume of 148 shares.
Cullinan Oncology Stock Down 3.3 %
The company has a market cap of $547.34 million, a PE ratio of 5.40 and a beta of -0.09. The business's fifty day moving average is $12.64 and its 200-day moving average is $12.65.
Get
Cullinan Oncology alerts:
Insiders Place Their Bets
In other Cullinan Oncology news, insider Jennifer Michaelson sold 4,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 27th. The shares were sold at an average price of $12.40, for a total transaction of $49,600.00. Following the sale, the insider now owns 53,031 shares in the company, valued at approximately $657,584.40. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 7.50% of the stock is owned by company insiders.
Institutional Investors Weigh In On Cullinan Oncology
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rock Springs Capital Management LP raised its stake in Cullinan Oncology by 1.0% during the 1st quarter. Rock Springs Capital Management LP now owns 652,578 shares of the company's stock worth $6,832,000 after acquiring an additional 6,500 shares during the period. Dupont Capital Management Corp bought a new stake in Cullinan Oncology during the 1st quarter worth approximately $119,000. Victory Capital Management Inc. bought a new stake in Cullinan Oncology during the 3rd quarter worth approximately $538,000. Nisa Investment Advisors LLC raised its stake in Cullinan Oncology by 24.0% during the 3rd quarter. Nisa Investment Advisors LLC now owns 17,241 shares of the company's stock worth $222,000 after acquiring an additional 3,341 shares during the period. Finally, Silverarc Capital Management LLC raised its position in shares of Cullinan Oncology by 5.4% during the third quarter. Silverarc Capital Management LLC now owns 224,555 shares of the company's stock valued at $2,879,000 after buying an additional 11,465 shares during the last quarter. Institutional investors own 82.53% of the company's stock.
Cullinan Oncology Company Profile
(Get Rating)
Cullinan Oncology Inc, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer.
See Also
- Get a free copy of the StockNews.com research report on Cullinan Oncology (CGEM)
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML's November Rally Have Staying Power?
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ's Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
Receive News & Ratings for Cullinan Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
